Application of optimal design methodologies in clinical pharmacology experiments
- PMID: 19009585
- DOI: 10.1002/pst.354
Application of optimal design methodologies in clinical pharmacology experiments
Abstract
Pharmacokinetics and pharmacodynamics data are often analysed by mixed-effects modelling techniques (also known as population analysis), which has become a standard tool in the pharmaceutical industries for drug development. The last 10 years has witnessed considerable interest in the application of experimental design theories to population pharmacokinetic and pharmacodynamic experiments. Design of population pharmacokinetic experiments involves selection and a careful balance of a number of design factors. Optimal design theory uses prior information about the model and parameter estimates to optimize a function of the Fisher information matrix to obtain the best combination of the design factors. This paper provides a review of the different approaches that have been described in the literature for optimal design of population pharmacokinetic and pharmacodynamic experiments. It describes options that are available and highlights some of the issues that could be of concern as regards practical application. It also discusses areas of application of optimal design theories in clinical pharmacology experiments. It is expected that as the awareness about the benefits of this approach increases, more people will embrace it and ultimately will lead to more efficient population pharmacokinetic and pharmacodynamic experiments and can also help to reduce both cost and time during drug development.
Copyright (c) 2008 John Wiley & Sons, Ltd.
Similar articles
-
Optimal design of pharmacokinetic studies.Basic Clin Pharmacol Toxicol. 2010 Mar;106(3):250-5. doi: 10.1111/j.1742-7843.2009.00533.x. Epub 2010 Jan 20. Basic Clin Pharmacol Toxicol. 2010. PMID: 20102362 Review.
-
Design of population pharmacokinetic experiments using prior information.Xenobiotica. 2007 Oct-Nov;37(10-11):1311-30. doi: 10.1080/00498250701553315. Xenobiotica. 2007. PMID: 17968747 Review.
-
Incorporating correlation in interindividual variability for the optimal design of multiresponse pharmacokinetic experiments.J Biopharm Stat. 2008;18(2):342-58. doi: 10.1080/10543400701697208. J Biopharm Stat. 2008. PMID: 18327725
-
A program for the optimum design of pharmacokinetic, pharmacodynamic, drug metabolism and drug-drug interaction models.Comput Methods Programs Biomed. 2005 Jun;78(3):237-49. doi: 10.1016/j.cmpb.2005.02.005. Epub 2005 Apr 22. Comput Methods Programs Biomed. 2005. PMID: 15899308
-
[Role of pharmacokinetic-pharmacodynamic relationships in drug development].Therapie. 2002 Jul-Aug;57(4):347-57. Therapie. 2002. PMID: 12422555 French.
Cited by
-
Optimal design in population kinetic experiments by set-valued methods.AAPS J. 2011 Dec;13(4):495-507. doi: 10.1208/s12248-011-9291-8. Epub 2011 Jul 15. AAPS J. 2011. PMID: 21761248 Free PMC article.
-
Population Fisher information matrix and optimal design of discrete data responses in population pharmacodynamic experiments.J Pharmacokinet Pharmacodyn. 2011 Aug;38(4):449-69. doi: 10.1007/s10928-011-9203-7. Epub 2011 Jun 10. J Pharmacokinet Pharmacodyn. 2011. PMID: 21660504
-
Structural identifiability and sensitivity.J Pharmacokinet Pharmacodyn. 2019 Apr;46(2):127-135. doi: 10.1007/s10928-019-09624-9. Epub 2019 Mar 20. J Pharmacokinet Pharmacodyn. 2019. PMID: 30895420
-
Modeling the responses to resistance training in an animal experiment study.Biomed Res Int. 2015;2015:914860. doi: 10.1155/2015/914860. Epub 2015 Jan 28. Biomed Res Int. 2015. PMID: 25695093 Free PMC article.
-
Study design and population pharmacokinetic analysis of a phase II dose-ranging study of interleukin-1 receptor antagonist.J Pharmacokinet Pharmacodyn. 2016 Feb;43(1):1-12. doi: 10.1007/s10928-015-9450-0. J Pharmacokinet Pharmacodyn. 2016. PMID: 26476629 Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources